Meclizine Hydrochloride interactions

Checked as Meclizine in this data source.

Full monograph for Meclizine Hydrochloride Check it against another medicine

Medicines

167 documented

Severity

Mechanism

Medicines documented to interact with Meclizine Hydrochloride, worst severity first.
Medicine	Severity	Mechanism	Effect	Sources
Potassium Chloride	Major	Others	Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants…	15 sources — open the full entry
Potassium Citrate	Major	Synergy	Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants…	15 sources — open the full entry
Potassium Citrate + Citric Acid	Major	Synergy	Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants…	15 sources — open the full entry
Sodium Chloride + Potassium Chloride + Sodium Acetate	Major	Others	Concomitant use of agents with anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants…	15 sources — open the full entry
Topiramate	Major	Synergy	Certain drugs such as carbonic anhydrase inhibitors and drugs with anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics…	9 sources — open the full entry
Zonisamide	Major	Synergy	Certain drugs such as carbonic anhydrase inhibitors and drugs with anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics…	9 sources — open the full entry
Aclidinium Bromide + Formoterol Fumarate	Moderate	Synergy	The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary…	12 sources — open the full entry
Alprazolam	Moderate	Synergy	Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these…	44 sources — open the full entry
Amantadine Hydrochloride	Moderate	Synergy	The anticholinergic-like adverse effects of amantadine may be potentiated by agents with anticholinergic properties such as antihistamines, antispasmodics…	6 sources — open the full entry
Amitriptyline Hydrochloride	Moderate	Synergy	Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic…	19 sources — open the full entry
Amitriptyline Hydrochloride + Chlordiazepoxide	Moderate	Synergy	Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic…2 documented mechanisms	63 sources — open the full entry
Aripiprazole	Moderate	Synergy	Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic…	19 sources — open the full entry
Asenapine Maleate	Moderate	Synergy	Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic…	19 sources — open the full entry
Atropine Sulfate (Injection)	Moderate	Synergy	Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic…	19 sources — open the full entry
Baclofen	Moderate	Synergy	Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these…	44 sources — open the full entry
Beclometasone + Formoterol + Glycopyrronium	Moderate	Synergy	Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic…	19 sources — open the full entry
Bethanechol Chloride	Moderate	Antagonism	Anticholinergic agents and other agents with significant anticholinergic activity (e.g., clozapine, class IA antiarrhythmics especially disopyramide) may…	2 sources — open the full entry
Brexpiprazole	Moderate	Synergy	Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic…	19 sources — open the full entry
Brivaracetam	Moderate	Synergy	Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these…	44 sources — open the full entry
Bromocriptine Mesylate	Moderate	Synergy	Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these…	44 sources — open the full entry
Budesonide + Glycopyrronium Bromide + Formoterol Fumarate	Moderate	Synergy	Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic…	19 sources — open the full entry
Carbamazepine	Moderate	Synergy	Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these…	44 sources — open the full entry
Carbidopa + LevodopaExtended release Prolonged release	Moderate	Synergy	Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these…	36 sources — open the full entry
Cariprazine	Moderate	Synergy	Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic…	19 sources — open the full entry
Carisoprodol	Moderate	Synergy	Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these…	44 sources — open the full entry
Cenobamate	Moderate	Synergy	Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these…	44 sources — open the full entry
Cetirizine Hydrochloridebase Ophthalmic	Moderate	Synergy	Concurrent use of cetirizine or levocetirizine with alcohol or other agents that exhibit central nervous system (CNS) depressant effects may result in additive…	10 sources — open the full entry
Chloral Hydrate	Moderate	Synergy	Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these…	44 sources — open the full entry
Chlorpheniramine Maleate	Moderate	Synergy	Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic…	19 sources — open the full entry
Chlorpromazine Hydrochloride	Moderate	Synergy	Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic…	19 sources — open the full entry
Cinnarizine + Dimenhydrinate	Moderate	Synergy	Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic…	19 sources — open the full entry
Citalopram Hydrobromide	Moderate	Synergy	Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these…	44 sources — open the full entry
Clobazam	Moderate	Synergy	Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these…	44 sources — open the full entry
Clomipramine Hydrochloride	Moderate	Synergy	Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic…	19 sources — open the full entry
Clonazepam	Moderate	Synergy	Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these…	44 sources — open the full entry
Clonidine Hydrochloride	Moderate	Synergy	Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these…	44 sources — open the full entry
Clozapine	Moderate	Synergy	Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic…	19 sources — open the full entry
Cyclizine Hydrochloride	Moderate	Synergy	Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic…	19 sources — open the full entry
Cyclobenzaprine Hydrochloride	Moderate	Synergy	Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic…	19 sources — open the full entry
Dacomitinib	Moderate	Metabolism	Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced…	1 sources — open the full entry
Dantrolene Sodium	Moderate	Synergy	Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these…	36 sources — open the full entry
Darifenacin	Moderate	Synergy	Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic…	19 sources — open the full entry
Desvenlafaxine Succinate	Moderate	Synergy	Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these…	44 sources — open the full entry
Deutetrabenazine	Moderate	Synergy	Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these…	44 sources — open the full entry
Dexmedetomidine	Moderate	Synergy	Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these…	44 sources — open the full entry
Dextromethorphan + Bupropion	Moderate	Synergy	Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these…	44 sources — open the full entry
Dextromethorphan + Phenylephrine + Triprolidine	Moderate	Synergy	Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these…2 documented mechanisms	63 sources — open the full entry
Dextromethorphan + Pseudoephedrine + Triprolidine	Moderate	Synergy	Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these…2 documented mechanisms	63 sources — open the full entry
Dextromethorphan Hydrobromide	Moderate	Synergy	Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these…	44 sources — open the full entry
Dextromethorphan Hydrobromide + Guaifenesin	Moderate	Synergy	Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these…	44 sources — open the full entry

Food & lifestyle

alcohol
Moderate
Synergy
Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous. In addition, the potential for abuse may be increased with the combination. The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system.
What to do: Alcohol should generally be avoided during therapy with anticholinergic agents. Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.
1 source
1. Linnoila M "Drug effects on psychomotor skills related to driving: interaction of atropine, glycopyrrhonium and alcohol." Eur J Clin Pharmacol 6 (1973): 107-12

Conditions

Conditions in which Meclizine Hydrochloride needs care, as documented in this source.

Anticholinergic Syndrome
Moderate
Antihistamines often have anticholinergic activity, to which elderly patients are particularly sensitive. Therapy with antihistamines should be administered cautiously, if at all, in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders. Conventional, first-generation antihistamines such as the ethanolamines (bromodiphenhydramine, carbinoxamine, clemastine, dimenhydrinate, diphenhydramine, doxylamine, phenyltoloxamine) tend to exhibit substantial anticholinergic effects. In contrast, the newer, relatively nonsedating antihistamines (e.g., cetirizine, fexofenadine, loratadine) reportedly have low to minimal anticholinergic activity at normally recommended dosages and may be appropriate alternatives.
20 sources
1. Schuller DE, Turkewitz D "Adverse effects of antihistamines." Postgrad Med 79 (1986): 75-86
2. "Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories (2002):
3. "Product Information. Chlor-Trimeton (chlorpheniramine)." Schering-Plough
4. "Product Information. Periactin (cyproheptadine)." Merck & Co., Inc (2002):
5. "Product Information. Benadryl (diphenhydramine)." Parke-Davis (2002):
6. "Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories (2001):
7. "Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation (2001):
8. "Product Information. Antivert (meclizine)." Roerig Division (2001):
Show all 20 sourcesShow fewer sources
1. "Product Information. Marezine (cyclizine)." Glaxo Wellcome (2001):
2. "Product Information. Optimine (azatadine)." Schering Corporation (2001):
3. "Product Information. Semprex-D (acrivastine-pseudoephedrine)." Endo Laboratories LLC (2001):
4. "Product Information. Zyrtec (cetirizine)." Pfizer U.S. Pharmaceuticals (2001):
5. "Product Information. Drixoral (dextromethorphan)." Schering-Plough (2001):
6. "Product Information. Poly-Histine-D (pyrilamine)." Bock Pharmacal Company (2001):
7. Watemberg NM, Roth KS, Alehan FK, Epstein CE "Central anticholinergic syndrome on therapeutic doses of cyproheptadine." Pediatrics 103 (1999): 158-60
8. "Product Information. Vistaril (hydroxyzine)." Pfizer U.S. Pharmaceuticals (2001):
9. "Product Information. Dramamine (dimenhydrinate)." Pharmacia and Upjohn (2001):
10. "Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation (2001):
11. "Product Information. Temaril (trimeprazine)." Allergan Inc (2001):
12. Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange (1999):
Asthma
Moderate
It has been suggested that the anticholinergic effect of antihistamines may reduce the volume and cause thickening of bronchial secretions, resulting in obstruction of respiratory tract. Some manufacturers and clinicians recommend that therapy with antihistamines be administered cautiously in patients with asthma or chronic obstructive pulmonary disease.
17 sources
1. "Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories (2002):
2. "Product Information. Chlor-Trimeton (chlorpheniramine)." Schering-Plough
3. "Product Information. Periactin (cyproheptadine)." Merck & Co., Inc (2002):
4. "Product Information. Benadryl (diphenhydramine)." Parke-Davis (2002):
5. "Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories (2001):
6. Maddox DE, Reed CE "Clinical pharmacodynamics of antihistamines." Ann Allergy 59 (1987): 43-8
7. "Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation (2001):
8. "Product Information. Antivert (meclizine)." Roerig Division (2001):
Show all 17 sourcesShow fewer sources
1. "Product Information. Marezine (cyclizine)." Glaxo Wellcome (2001):
2. "Product Information. Optimine (azatadine)." Schering Corporation (2001):
3. "Product Information. Semprex-D (acrivastine-pseudoephedrine)." Endo Laboratories LLC (2001):
4. "Product Information. Drixoral (dextromethorphan)." Schering-Plough (2001):
5. "Product Information. Poly-Histine-D (pyrilamine)." Bock Pharmacal Company (2001):
6. "Product Information. Vistaril (hydroxyzine)." Pfizer U.S. Pharmaceuticals (2001):
7. "Product Information. Dramamine (dimenhydrinate)." Pharmacia and Upjohn (2001):
8. "Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation (2001):
9. "Product Information. Temaril (trimeprazine)." Allergan Inc (2001):
Cardiovascular Diseases
Moderate
Antihistamines may infrequently cause cardiovascular adverse effects related to their anticholinergic and local anesthetic (quinidine-like) activities. Tachycardia, palpitation, ECG changes, arrhythmias, hypotension, and hypertension have been reported. Although these effects are uncommon and usually limited to overdosage situations, the manufacturers and some clinicians recommend that therapy with antihistamines be administered cautiously in patients with cardiovascular disease, hypertension, and/or hyperthyroidism.
15 sources
1. Schuller DE, Turkewitz D "Adverse effects of antihistamines." Postgrad Med 79 (1986): 75-86
2. "Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories (2002):
3. "Product Information. Chlor-Trimeton (chlorpheniramine)." Schering-Plough
4. "Product Information. Periactin (cyproheptadine)." Merck & Co., Inc (2002):
5. "Product Information. Benadryl (diphenhydramine)." Parke-Davis (2002):
6. "Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation (2001):
7. "Product Information. Antivert (meclizine)." Roerig Division (2001):
8. "Product Information. Optimine (azatadine)." Schering Corporation (2001):
Show all 15 sourcesShow fewer sources
1. Smith SJ "Cardiovascular toxicity of antihistamines." Otolaryngol Head Neck Surg 111 Suppl (1994): 348-54
2. "Product Information. Zyrtec (cetirizine)." Pfizer U.S. Pharmaceuticals (2001):
3. Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52
4. "Product Information. Drixoral (dextromethorphan)." Schering-Plough (2001):
5. "Product Information. Poly-Histine-D (pyrilamine)." Bock Pharmacal Company (2001):
6. "Product Information. Vistaril (hydroxyzine)." Pfizer U.S. Pharmaceuticals (2001):
7. "Product Information. Dramamine (dimenhydrinate)." Pharmacia and Upjohn (2001):
Liver Diseases
Moderate
Limited pharmacokinetic data are available for the older, first-generation antihistamines. Many appear to be primarily metabolized by the liver, and both parent drugs and metabolites are excreted in the urine. Patients with renal and/or liver disease may be at greater risk for adverse effects from antihistamines due to drug and metabolite accumulation. Therapy with antihistamines should be administered cautiously in such patients. Lower initial dosages may be appropriate.
15 sources
1. Glazko AJ, Dill WA, Young RM, Smith TC, Ogilvie RI "Metabolic disposition of diphenhydramine." Clin Pharmacol Ther 16 (1974): 1066-76
2. Paton DM, Webster DR "Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines)." Clin Pharmacokinet 10 (1985): 477-97
3. Rumore MM "Clinical pharmacokinetics of chlorpheniramine." Drug Intell Clin Pharm 18 (1984): 701-7
4. Huang SM, Athanikar NK, Sridhar K, Huang YC, Chiou WL "Pharmacokinetics of chlorpheniramine after intravenous and oral administration in normal adults." Eur J Clin Pharmacol 22 (1982): 359-65
5. Simons KJ, Simons FE, Luciuk GH, Frith EM "Urinary excretion of chlorpheniramine and its metabolites in children." J Pharm Sci 73 (1984): 595-9
6. Meredith CG, Christian CD Jr, Johnson RF, Madhavan SV, Schenker S "Diphenhydramine disposition in chronic liver disease." Clin Pharmacol Ther 35 (1984): 474-9
7. Blyden GT, Greenblatt DJ, Scavone JM, Shader RI "Pharmacokinetics of diphenhydramine and a demethylated metabolite following intravenous and oral administration." J Clin Pharmacol 26 (1986): 529-33
8. Albert KS, Hallmark MR, Sakmar E, Weidler DJ, Wagner JG "Pharmacokinetics of diphenhydramine in man." J Pharmacokinet Biopharm 3 (1975): 159-70
Show all 15 sourcesShow fewer sources
1. Simons FE, Frith EM, Simons KJ "The pharmacokinetics and antihistaminic effects of brompheniramine." J Allergy Clin Immunol 70 (1982): 458-64
2. Bruce RB, Turnbull LB, Newman JH, Pitts JE "Metabolism of brompheniramine." J Med Chem 11 (1968): 1031-4
3. Porter CC, Arison BH, Gruber VF, Titus DC, Vandenheuvel WJ "Human metabolism of cyproheptadine." Drug Metab Dispos 3 (1975): 189-97
4. Hintze KL, Wold JS, Fischer LJ "Disposition of cyproheptadine in rats, mice, and humans and identification of a stable epoxide metabolite." Drug Metab Dispos 3 (1975): 1-9
5. Maddox DE, Reed CE "Clinical pharmacodynamics of antihistamines." Ann Allergy 59 (1987): 43-8
6. Simons FE, Simons KJ, Frith EM "The pharmacokinetics and antihistaminic of the H1 receptor antagonist hydroxyzine." J Allergy Clin Immunol 73 (1984): 69-75
7. Simons FE, Watson WT, Chen XY, Minuk GY, Simons KJ "The pharmacokinetics and pharmacodynamics of hydroxyzine in patients with primary biliary cirrhosis." J Clin Pharmacol 29 (1989): 809-15

Therapeutic duplication

Drug classes that overlap with Meclizine Hydrochloride, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.

antivertigo agents
The recommended maximum number of medicines in the 'antivertigo agents' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'antivertigo agents' category.
Example product in the source data (US market): Meperidine/promethazine
antivertigo agents
The recommended maximum number of medicines in the 'antivertigo agents' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'antivertigo agents' category.
Example product in the source data (US market): Codeine/promethazine
antivertigo agents
The recommended maximum number of medicines in the 'antivertigo agents' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'antivertigo agents' category.
Example product in the source data (US market): Promethazine vc with codeine
antivertigo agents
The recommended maximum number of medicines in the 'antivertigo agents' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'antivertigo agents' category.
Example product in the source data (US market): Phenohytro
antivertigo agents
The recommended maximum number of medicines in the 'antivertigo agents' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'antivertigo agents' category.
Example product in the source data (US market): Promethazine dm
antivertigo agents
The recommended maximum number of medicines in the 'antivertigo agents' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'antivertigo agents' category.
Example product in the source data (US market): Phenylephrine/promethazine

Medicines

Food & lifestyle

alcohol

Conditions

Anticholinergic Syndrome

Asthma

Cardiovascular Diseases

Liver Diseases

Therapeutic duplication

antivertigo agents

antivertigo agents

antivertigo agents

antivertigo agents

antivertigo agents

antivertigo agents